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Modification of Biological Parameters After Treatment
With Recombinant Factor VIIa in a Patient With
Thrombocytopathy due to Storage Pool Disease
L. Langendonck and I.M. Appel*
Storage pool deficiencies (SPD) are a heterogenious
group of segregation abnormalities [1]. Distinct forms are
known such as gray platelet syndrome (GPS), d-SPD, and
ad-SPD where platelets lack a-granules, dense bodies,
or both to a variable degree [2]. The a-granules contain
substances like von Willebrand factor, fibronectine, and
platelet factor 4 (PF4)which are necessary for cell contact,
thrombin generation, and subsequent development of
platelet aggregates. Absence of a-granules in GPS, for
example, can be monitored by PF4 deficiency. The dense
bodies are a metabolically inert storage pool containing
ATP, ADP, serotonine, calcium, and pyrophosphate, all
of which are secreted in response to platelet activation.
Ind-SPD, the lowered amount ofADP leads to a diagnostic
raised ATP/ADP ratio. Patients suffering from d-SPD
present with easy bruising, petechiae, epistaxis, menor-
rhagia, and particularly postoperative and posttraumatic
bleeding. Treatment is usually symptomatic;most patients
respond to DDAVP, transfusions of platelet concentrates
are the most appropriate approach in excess bleeding.
However, with recurrent transfusions the risk of alloim-
munisation exists, leading to a refractory state.
An alternative treatment for patients with a thrombo-
cytopathy is recombinant factor VIIa (rFVIIa). The exact
mechanism of the beneficial effect of rVIIa is not fully
understood. Direct activation of small amounts of F Xa by
rVIIa might lead to thrombin generation on the platelet
surface itself compensating for the dysfunctionality of the
platelets [3].
FVIIa has been successfully used in a few patients
with Glanzmann Trombasthenia [4] and Bernard–Soulier
syndrome [5], as well as in patients with thrombocytope-
nia [6]. To the best of our knowledge, the use of rFVIIawas
described only once in an in vitro study of a casewith SPD
[7] and recently in a clinical study by Almeida [8].
We report a patient with a storage pool disease who
successfully underwent dental surgery during treatment
with rFVIIa.
A young male patient 13 years old, born from non-
consanguin Caucasian was diagnosed with d-SPD. He had
a prolonged bleeding time of 8–13 min and a normal
platelet count (170–220 109/L). General haemostatis
analyses concerning APTT, PT, thrombin time, and
fibrinogen revealed values within the normal range.
Platelet membrane glycoprotein complexes showed nor-
mal expression, but the patient had an elevated ATP/
ADP ratio of 5.5 measured in ethanol extracts with the
luciferin–luciferase assay. The dental surgeon advised
the extraction of three dental elements. After informed
consent we decided to analyze the effect of rFVIIa treat-
ment on SPD. During and 24 hr after this procedure the
patient was prophylactically treated with rFVIIa (Novo-
Seven1, Novo Nordisk, Copenhagen, Denmark) and the
anti-fibrinolytic agent tranexamic acid (Cyclokapron1,
Patients with thrombocytopathy due to
storage pool disease mostly suffer from mild
bleeding diathesis. However surgical interven-
tions can lead to excess bleeding. We describe
how treatment with recombinant factor VIIa
(Novoseven1) during a surgical procedure in a
boy with SPD leads to an immediate rise in PF-4,
thereby activating factor Xa on the platelet
surface, leading to active thrombin generation.
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Pharmacia&Upjohn, Capella aan den ijssel, The Nether-
lands), four times daily. At T¼ 0 the patient received a
bolus of rFVIIa (100 mg/kg) directly followed by a con-
tinuous infusion of 16 mg/kg/hr. During infusion, the
bleeding time and levels of factor VIIa, prothrombin
fragment1þ 2 (F1þ 2), TAT (Thrombin Antithrombin III
complex), D dimer, PF4, and Thrombin Activatable
Fibrinolysis Inhibitor (TAFI) were monitored. They were
checked after 15min (T¼ 0.25), 1 hr (T¼ 1), 5 hr (T¼ 5),
and 24 hr (T¼ 24) (Table I). The infusion rate was
calculated depending on the plasma factor VII level,
intended to reach plasma levels of 6–20 IU/ml. The ope-
ration was performed at T¼ 4. Blood samples were
collected in tubes containing 3.8% trisodiumcitrate for the
routine coagulation assays and in CTAD (citrate, theo-
phylline, adenosine, dipyridamole) tubes for D-dimer and
PF4 analysis. Samples were chilled immediately in an ice
bath, centrifuged at 47.800g for 30 min at 48C and stored
in 808C.
Bleeding time was measured according to Ivy. Factor
VII clotting activity was analyzed using a one step clotting
activity method containing factor VII deficient plasma.
F1þ 2 was measured using a commercial solid phase
enzyme linked immunosorbent assay (Enzygnost F1þ 2,
Behringwerke AG). TATwas determined with a commer-
cial solid phase enzyme linked immuosorbent assay
(Enzygnost TAT, Behringwerke AG, Marburg, Germany).
D-dimer was also measured with a sandwich assay
(Asserachrom1 D-dimer) for the quantitative determina-
tion of fibrin degradation products. PF4was quantitatively
determined with an enzyme immunoassay (Asserachrom
PF4). TAFI was measured with an enzyme linked immu-
nosorbent assay.
The increased levels of FVIIa gradually lead to a
normalization of the bleeding time. Increased thrombin
generation is demonstrated by high levels of both TAT
and F1þ 2 immediately after administration of rFVIIa. The
normal plasma levels of D-dimer suggests no degradation
of fibrin or fibrinogen; normal measured levels of TAFI do
not point to downregulation of fibrinolysis. An increase
in PF4 immediately after the bolus injection of rFVIIa
indicates the induction of platelet aggregation.
The use of recombinant factor VIIa in this patient with a
storage pool disease leads to a normal hemostasis during
and after the extraction of three dental elements. The
underlyingmechanisms bywhich the use of rFVIIa results
in normal hemostasis in a patient with storage pool disease
remain to be determined, but two possibilities are evident:
a mechanism of enhanced thrombin generation or of in-
hibited fibrinolysis.
Enhanced thrombin generation is reflected by elevation
of F1þ 2 and by the release of TAT. Considering the half
lifes of F1þ 2 and TAT being, respectively, 90 and 3 min,
thrombin generation seems an important process directly
following the administration of rFVIIa. As expected, the
rFVIIa infusion induces thrombin generation by activating
the extrinsic pathway in a tissue-factor dependent manner.
FVIIa reaches the expected elevated levels. The immedi-
ate rise in TAT and F1þ 2 appears already before any
surgical event has taken place. This suggests immediate
activation of thrombin generation not by the release of
tissue factor but possibly by a tissue factor-independent
pathway. Activation of small amounts of F Xa in the
proximity to platelet surfaces can lead to an explosion of
thrombin generation [3,9]. In our patient, we assume
that rFVIIa binds to activated platelets activating Xa,
generated on the platelet surface, hence leading to
formation of the prothrombinase complex. As is demon-
strated in the table the bolus injection of rFVIIa indeed
leads to an immediate rise in PF-4 values. This may result
in active aggregation of platelets by the brief release of
a high amount of alpha-granule-specific PF-4, finally
leading to the explosion of thrombin generation as men-
tioned above.
TAFI demonstrates no significant changes. High con-
centrations of thrombin seem to be necessary for the
activation of TAFI [10]. Downregulation of fibrinolysis
by TAFI activation has been demonstrated in in vitro
studies to be an important factor in clot stabilization [11].
Until now this effect has not been monitored in in vivo
situations.
In this patient with SPD, infusion of rFVIIa does not
lead to a change in D-dimers nor to a rise in TAFI in a state
of active thrombin generation.
TABLE I. Biological Parameters Before (T¼24 hr) and During (T0–T24) Treatment With












24 0.97 0.53 1.90 112 336 Nd 8.00
0 0.95 0.52 2.40 117 200 10 7.50
0.25 54.40 3.40 79.90 132 217 1711 6.50
1 41.20 1.71 63.00 117 189 56 5.25
5 25.70 3.41 74.10 82 265 199 3.15
24 12.80 6.08 50.20 113 497 64 5.25
Normal range 0.9–1.1 0.4–1.1 1.0–4.1 60–138 <500 0–5 <5
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In conclusion, this patient with SPD demonstrates
an increased thrombin generation possibly enhanced
by triggering of the extrinsic pathway by rFVIIa. Incre-
ased levels of thrombin at the site of injury due to the
operation might induce platelet aggregation. On the other
hand, a tissue factor-independent activation of FXa
occurs probably by the binding of rFVIIa to platelet
surfaces, leading to an immediate burst of thrombin
generation. This is demonstrated by elevated levels of
PF-4 and the rise of TAT and F1þ 2, immediately after the
infusion of rFVIIa even before surgical damage to the
tissues.
Recombinant FVIIa demonstrates to be a safe alter-
native to platelet transfusions during surgical interven-
tions in a patient with SPD. No adverse effects were
observed.
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